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Patients with systemic sclerosis may develop borderline
pulmonary arterial pressure. The clinical relevance of
this condition is not always clear. Reported data support
the evidence that this subgroup may represent an
intermediate stage between normal pulmonary arterial
pressure and manifest pulmonary arterial hypertension,
a serious complication in scleroderma. Recognizing the
clinical relevance of borderline pulmonary arterial
pressure increase in scleroderma patients, future studies
should aim for clear evidence for diagnostic and
therapeutic algorithms for this population.antibody, NT-proBNP), lung functional (for example,In their recent study, Visovatti and colleagues [1] present
a detailed analysis of patients with borderline pulmonary
arterial pressure (PAP) as a subgroup analysis of the DE-
TECT study, providing important clinical data for under-
standing early pulmonary vasculopathy in patients with
systemic sclerosis.
In fact, every physician who has observed the dramatic
deterioration of patients with pulmonary arterial hyper-
tension (PAH) and successive right ventricular failure
would urge for the earlier recognition and therapy of
this devastating condition. About 10% of all scleroderma
patients may develop PAH [2], which - besides lung fi-
brosis - represents the most frequent cause of death in
this patient population [3]. But can PAH be recognized
at an early stage and maybe even prevented?
If we assume that the increase of PAP is a process lasting
for a longer period of time, there must be a phase of tran-
sition from normal (mean PAP ≤20 mmHg) pulmonary
hemodynamic conditions to PAH (mean PAP ≥25 mmHg).
Patients in this so-called 'borderline' range may represent
the early stage of PAH. Earlier studies found that such* Correspondence: gabor.kovacs@klinikum-graz.at
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article, unless otherwise stated.patients were more likely to develop pulmonary hyper-
tension than patients with mean PAP ≤20 mmHg, with a
hazard ratio of 3.7 [4]. The rate of borderline patients de-
veloping PAH was 19% after 3 years and 27% after 5 years.
Accordingly, we may argue that borderline PAP is a 'pre-
PAH' condition in scleroderma. Of course, borderline
elevation of PAP may be caused not only by pulmonary
vasculopathy but also by cardiac or pulmonary co-
morbidities [5]. In these cases borderline elevation of PAP
may be considered as a general prognostic marker [5,6].
The analysis of Visovatti and colleagues [1] includes sev-
eral clinical (for example, current/past telangiectasis, pres-
ence of peripheral edema), laboratory (for example, ACA
forced vital capacity (percentage predicted)/diffusion cap-
acity for carbon monoxide ratio) and cardiac (for example,
tricuspid annular plane systolic excursion) markers that
may distinguish scleroderma patients with borderline PAP
elevation from those with normal PAP or with manifest
PAH. According to this analysis, borderline elevation of
PAP in scleroderma patients may represent an intermedi-
ate stage in the continuum between normal PAP and
manifest PAH.
Among the DETECT population, 15% of all patients
presented with borderline PAP hemodynamics. Although
this number may be different in the general scleroderma
population, due to the strict inclusion and exclusion cri-
teria of the DETECT study [7], the borderline population
seems to be a substantial subgroup. Unfortunately,
follow-up data of the described patients in comparison
with normal PAP and manifest PAH patients have not
been provided. Such data might impact the develop-
ment of clinical algorithms regarding further follow-
up and treatment of these patients.
In addition to the borderline elevation of resting PAP,
another specific hemodynamic situation in scleroderma
patients needs careful interpretation: exercise-induced
PAP increase. Earlier studies showed that this may be a
frequent condition among scleroderma patients anded Central. This is an Open Access article distributed under the terms of the
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frequent in this population [2]. In a recent analysis, a
strong correlation between resting and exercise PAP
values was evident [5], suggesting that patients with
borderline hemodynamics and those with a strong PAP
increase during exercise may strongly overlap, closing
the gap between these two hemodynamic conditions.
The most important question remains open: should
targeted PAH therapy be offered to scleroderma patients
with borderline PAP or exercise-induced PAP increase?
Unfortunately there has been no clinical study investi-
gating patients with borderline PAP so far and only two
small studies have selected patients with exercise-
induced PAP increase [8,9]. The results of these studies
are promising, but need to be confirmed in adequately
powered, randomized, prospective trials.
Based on a series of studies indicating borderline
hemodynamics has an important role in scleroderma
patients with regard to the development of PAH and
potentially for early treatment, future studies should
aim for clear evidence for diagnostic and therapeutic algo-
rithms for this patient population. This may contribute
to a substantial prognostic improvement for patients
with scleroderma who develop pulmonary vasculopathy
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